Bioventus Inc. (NASDAQ: BVS) is a Healthcare company (Medical - Devices) with a market capitalization of $726M. The Maz Rating grades it against the other companies in its sector.
Bioventus Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.60, Bioventus Inc. trades at 12.4x trailing earnings, 1.2x sales and 3.0x book value, with an EV/EBITDA of 9.2. Over the last twelve months it generated about $590M of revenue and $58M of net income. It runs a gross margin of 68.3%, an operating margin of 10.1% and a net margin of 9.8%. It shows return on equity of 27.2%, return on invested capital of 11.0% and a free cash flow yield of 11.8%. On the balance sheet: a debt-to-equity ratio of 1.02 and a current ratio of 1.68. Over the past 52 weeks the share price ranged from $6.47 to $15.89, with a beta of 0.62.
Bioventus Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.